A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Organogenesis Holdings Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 500 shares of ORGO stock, worth $1,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 3,800 86.84%
Holding current value
$1,590
Previous $10,000 90.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.42 - $3.24 $112,198 - $150,216
-46,363 Reduced 25.17%
137,854 $394,000
Q2 2024

Aug 14, 2024

SELL
$2.28 - $3.03 $99,667 - $132,453
-43,714 Reduced 19.18%
184,217 $515,000
Q1 2024

May 15, 2024

SELL
$2.61 - $4.49 $602,547 - $1.04 Million
-230,861 Reduced 50.32%
227,931 $647,000
Q4 2023

Feb 14, 2024

SELL
$1.97 - $4.21 $315,164 - $673,524
-159,982 Reduced 25.85%
458,792 $1.88 Million
Q3 2023

Nov 14, 2023

SELL
$2.34 - $4.43 $2.91 Million - $5.5 Million
-1,242,416 Reduced 66.75%
618,774 $1.97 Million
Q2 2023

Aug 14, 2023

SELL
$1.9 - $4.3 $1.31 Million - $2.97 Million
-690,700 Reduced 27.07%
1,861,190 $6.18 Million
Q1 2023

May 15, 2023

BUY
$1.89 - $2.93 $3.55 Million - $5.5 Million
1,876,307 Added 277.73%
2,551,890 $5.44 Million
Q4 2022

Feb 14, 2023

SELL
$2.48 - $3.43 $1.12 Million - $1.55 Million
-451,546 Reduced 40.06%
675,583 $1.82 Million
Q3 2022

Nov 14, 2022

BUY
$3.14 - $6.43 $1.2 Million - $2.47 Million
383,714 Added 51.62%
1,127,129 $3.65 Million
Q2 2022

Aug 15, 2022

SELL
$4.74 - $8.15 $207,995 - $357,630
-43,881 Reduced 5.57%
743,415 $3.63 Million
Q1 2022

May 16, 2022

BUY
$6.47 - $9.57 $3.76 Million - $5.56 Million
580,717 Added 281.11%
787,296 $6 Million
Q4 2021

Feb 14, 2022

SELL
$9.02 - $13.5 $2.03 Million - $3.04 Million
-225,522 Reduced 52.19%
206,579 $1.91 Million
Q3 2021

Nov 15, 2021

SELL
$13.71 - $17.18 $2.17 Million - $2.72 Million
-158,456 Reduced 26.83%
432,101 $6.15 Million
Q2 2021

Aug 16, 2021

BUY
$14.92 - $23.23 $1.18 Million - $1.83 Million
78,946 Added 15.43%
590,557 $9.82 Million
Q1 2021

May 17, 2021

BUY
$7.33 - $21.06 $2.82 Million - $8.11 Million
385,068 Added 304.3%
511,611 $9.32 Million
Q4 2020

Feb 16, 2021

BUY
$3.63 - $7.53 $459,351 - $952,868
126,543 New
126,543 $953,000
Q2 2020

Aug 14, 2020

SELL
$2.86 - $4.61 $67,824 - $109,326
-23,715 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$2.92 - $5.31 $114,501 - $208,221
-39,213 Reduced 62.31%
23,715 $77,000
Q4 2019

Feb 14, 2020

BUY
$4.7 - $8.11 $203,260 - $350,733
43,247 Added 219.74%
62,928 $303,000
Q3 2019

Nov 14, 2019

SELL
$3.57 - $8.09 $23,672 - $53,644
-6,631 Reduced 25.2%
19,681 $129,000
Q2 2019

Aug 14, 2019

BUY
$6.58 - $8.69 $173,132 - $228,651
26,312 New
26,312 $200,000

Others Institutions Holding ORGO

About Organogenesis Holdings Inc.


  • Ticker ORGO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 130,888,000
  • Market Cap $416M
  • Description
  • Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokin...
More about ORGO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.